HTT and Huntington disease: This study confirms findings that 3-NPA, a pharmacological inducer of HD, exacerbates the effects of the mutant HTT and causes a more significant decrease in cell viability in an established striatal cell model of HD compared to healthy cells, a finding supported by 3-NPA’s extensive use as a pharmacological model of HD in vivo and in vitro models [28].